Kornimate/medical-research-clean huggingface dataset:
atrial and ventricular wall stress during breathing

Conditions: Healthy

Summary: healthy reclining adult volunteers, with valsalva manoeuver, muller manoeuver, light continuous positive airway pressure by mask, passive leg raising, and maximal hand-grip. ultrasound heart images captured before and during.

with focus on atrial wall strain and strain-rate, in healthy volunteer adult subjects, heart ultrasound is recorded during resting, valsalva manoeuver, muller manoeuver, passive leg raising, and handgrip. echocardiographic recordings are made before and during each intervention. participants are otherwise resting in a reclined position.

Eligibility criteria:
inclusion criteria: * healthy adults exclusion criteria: * known heart or lung disease
is myocardial stunning induced by continuous renal replacement therapy a reality in critically ill patients?

Conditions: Acute Kidney Injury KDIGO 3; Continuous Renal Replacement Therapy Initiated by the Clinician in Charge Without Emergency; Myocardial Stunning

Summary: myocardial stunning during chronic intermittent hemodialysis is a well-described phenomenon. little case series of patients presenting myocardial stunning during renal replacement therapy for acute kidney injury in critically ill patients are reported, with intermittent hemodialysis and continuous renal replacement therapy. however, the small sample sizes and the absence of a control arm limit their interpretation, mainly whether the myocardial stunning may be related to cardiac loading conditions variations and whether it may impact the hemodynamic. the investigator hypothesize that myocardial stunning induced by renal replacement therapy is frequent, independent from cardiac loading conditions and associated with peripheral hypoperfusion.


Eligibility criteria:
inclusion criteria: * age \> 18 years old * acute kidney injury grade 3 (kdigo) * indication for renal replacement therapy for the clinician in charge exclusion criteria: * emergency indication to renal replacement therapy (ph\ 6mmol/l, refractory pulmonary oedema) * poor echogenicity with speckle tracking analysis failure * chronic hemodialysis * extra corporeal membrane oxygenation, left ventricular assist device.

Keywords: acute kidney injury, continuous renal replacement therapy myocardial stunning regional wall motion abnormalities 2d speckle tracking echocardiography
olfactory training on smell dysfunction patients in hk

Conditions: Olfaction Disorders; Smell Disorders; Anosmia; Hyposmia; Olfactory Impairment; Smell Loss; Smell Dysfunction

Summary: * causes of olfactory dysfunction can be classified into conductive and sensorineural causes. * conductive causes are mainly due to structural nasal problem, which can be treated by nasal surgery * sensorineural causes included post-infection, post-head injury, post head and neck irradiation and other central nervous system diseases. * olfactory training is well established treatment for sensorineural olfactory dysfunction in foreign countries. * olfactory training by neurological chemosensory stimulation using aromatic substances delivered via electronic portable aromatic rehabilitation (epar) diffuser was proved to be effective treatment in covid-19 related olfactory dysfunction in recent hong kong study. * however, there is a lack of local study on the effect of olfactory training in other non-covid-19 sensorineural causes of olfactory dysfunction in hong kong population.

design prospective double-blinded randomized control trial. study period 1/7/2022 - 30/6/2024 for case recruitment. suitable patient will be recruited. informed consent will be signed. objective smell assessment will be done using the university of pennsylvania smell identification test (upsit) and butanol threshold test (btt). subjective quality of life score will be obtained by sino-nasal outcome test (snot-22). subjective smell and taste assessment will be assessed by visual analogue scale (vas). patient will be randomized into treatment group and control group using computer generated list by an independent nursing staff. doctors and the patients will be blinded during the study.

Eligibility criteria:
inclusion criteria: * olfactory dysfunction \> 6 months and \< 5 years exclusion criteria: * history of significant head injury (fracture, ich) * history of brain surgery * history of nasal surgery * active nasal disease * active neurological disease * poor premorbid status/ non-communicable patients * mentally incompetent patients * \<18 years' old * pregnancy * hypersensitivity to the aromatic substance.
n-cpap versus n-bipap and nippv for postextubation in rds in preterms

Conditions: Respiratory Distress Syndrome

Summary: non-invasive ventilation in preterms complaining from rds a randomized, controlled trial to compare between capap, n-bipap and nippv

the primary aim of this study is to compare the impact of early extubation to nasal continuous positive airway pressure (n-cpap) versus nasal bilevel positive airway pressure (n-bipap) and non invasive positive pressure ventilation(nippv) on the need for mechanical ventilation via endotracheal tube (mvet) to 7 days of age or less in preterm infants less than or equal to 34 weeks' gestation requiring intubation and surfactant if indicated for respiratory distress syndrome within 120 min of delivery . second aim is to compare different outcomes of post-extubation n-cpap , n-bipapand nippv.

Eligibility criteria:
inclusion criteria: * preterm infants lessthan 34wk exclusion criteria: * preterms less than 1000 g birth weight * infants with apgar 0at 1 min * presenceofany other cause of respiratory distress as: congenital malformation affecting the cardiorespiratory system ,neuromuscular disease ,fetal hydrops , interventricular hemorrhage and chromosomal aberrations
transcranial photobiomodulation with patients with parkinson's disease

Conditions: Parkinson Disease

Summary: parkinson's disease (pd) is the second most common neurodegenerative disorder after alzheimer's disease. it is a progressive and disabling disease with significative impact on quality of life. since it has no cure, available treatment is targeted to improve the symptoms due to a lack of dopamine in the central nervous system. the aim of the study was to see how transcranial photobiomodulation (tpbm) helped patients with parkinson's disease.


Eligibility criteria:
inclusion criteria: * idiopathic pd, * hoehn \& yahr stage i-iv, * independent gait with or without technical assistance * stable parkinsonian medication for at least a month before the study star. exclusion criteria: * comorbidities that affect balance or walking, * other neurological pathologies besides pd, * chronic diseases not medically controlled and participation in another physiotherapy program or sport activity during the intervention period or in the month before starting the study

Keywords: transcranial photobiomodulation, posture instability, parkinson's disease, modified parkinson activity scale, biodex balance system
the effects of intra operative hand reflexology for patients receiving out patient vein surgery

Conditions: Pain; Anxiety

Summary: this randomised controlled trial aims to compare the effectiveness of hand reflexology received during office based vein surgery, under local anaesthetic on patient's reports of pain and anxiety, compared to usual standard care.

the negative effects of anxiety and pain on surgical recovery are well documented. it is also accepted that distraction can be effective in pain reduction. this randomised controlled trial will explore the effect of intra operative hand reflexology on pain perception and anxiety during office-based surgery under local anaesthetic. participants will be randomly allocated to either the experimental condition, in which they will receive a hand reflexology during treatment, or control condition in which they will receive usual standard care. immediate and longer term outcomes will be explored. eight weeks after surgery, participants will return to the clinic for a follow up appointment. while they are in the waiting area they will be asked to complete a short questionnaire to assess time taken to return to pre surgical levels of functioning, pain experienced in the first four weeks after surgery, severity of venous symptoms and satisfaction with treatment.

Eligibility criteria:
inclusion criteria: * to be aged between 18 and 80 * to be able to give informed consent * to be receiving, endovenous laser ablation or phlebectomies for the treatment of varicose veins * to have a good understanding of written and spoken english. * to arrive at the clinic with sufficient time before their procedure to give consent and complete the questionnaire (\>20 mins) exclusion criteria: -to be aged under 18 or over 80

Keywords: randomised controlled trial pain anxiety ambulatory surgery hand massage local anaesthetic
neutrophile gelatinase associated lipocalin evaluation in septic acute kidney injury

Conditions: Acute Kidney Failure

Summary: acute kidney injury (aki) is a major organ failure in septic shock. current medical tests (serum creatinine and urea) cannot identify aki until approximately 48 hours after it occurs. neutrophil gelatinase-associated lipocalin (ngal) may be able to predict ischemic aki more effectively and faster than serum creatinine and urea levels. the purpose of this study is to take a blood sample from patients at admission and then at 24 and 48 hours after to test their plasma for ngal and compare the ngal levels to their creatinine and urea levels. the investigators hypothesize that ngal is an earlier marker to classify the kidney failure as acute tubular necrosis or pre-renal azotemia than creatinine and urea.

primary outcome measures: to correlate elevated serum ngal with the diagnosis of intrinsic acute kidney injury in septic shock secondary outcome measures : to compare serum ngal with serum creatinine, serum urea and urine output in septic aki death within the intensive care unit death from all causes at 28 days after inclusion

Eligibility criteria:
inclusion criteria: * patients showing signs of infection and hypotension requiring the use of epinephrine despite of an appropriate fluid challenge. * 18 years of age or older exclusion criteria: * age under 18 years * prisoners or other institutionalized or vulnerable individuals * participation in an interventional clinical study within the previous 30 days

Keywords: septic shock medical intensive care
breath analysis in obstructive sleep apnoea

Conditions: Obstructive Sleep Apnoea (OSA)

Summary: clinical trial in patients with obstructive sleep apnoea that are randomised to either continue or withdraw continuous positive airway pressure therapy to identify a disease-specific exhaled breath pattern by mass spectrometry.

randomised placebo-controlled trial (therapeutic vs. subtherapeutic continuous positive airway pressure \[cpap\]) including 30 osa patients to define the effects of cpap withdrawal (subtherapeutic cpap) on the composition of exhaled breath analysed by mass spectrometry for identification of osa specific markers.

Eligibility criteria:
inclusion criteria: * confirmed osa (at the time of original diagnosis) with an oxygen desaturation index (odi) of \>20/h. * currently \>20/h oxygen desaturations (≥4% dips) during an ambulatory nocturnal pulse oximetry performed on the last night of a 4-night period without cpap. * treated with cpap for more than 12 months, minimum compliance 4h/night, apnoea-hypopnoea index (ahi) \<10 with treatment (according to cpap- download) and current ess \<10. * age between 20 and 75 years at trial entry. exclusion criteria: * previous ventilatory failure (awake spo2 \ 6kpa). * unstable, untreated coronary or peripheral artery disease, severe arterial hypertension or hypotension (\>180/110 or \<90/60mmhg) * previously diagnosed with cheyne-stokes breathing. * current professional driver; any previous sleep related accident. * acute inflammatory disease. * acute or chronic hepatic disease. * renal failure or renal replacement therapy. * use of inhaled drugs.

Keywords: osa cpap exhaled breath
2b active: outpatient rehabilitation for adolescents with chronic pain

Conditions: Chronic Pain

Summary: the purpose of this study is to evaluate whether a multimodal rehabilitation program effectively reduces functional disability in adolescents with chronic musculoskeletal pain, compared to care as usual.


Eligibility criteria:
inclusion criteria: * age 12-21 years at the start of the study * complaints of chronic non-specific musculoskeletal pain of a duration \> 3 months * considerable activity limitations * fear of movement * indication for outpatient multidisciplinary rehabilitation treatment * adequate dutch literacy to complete the assessments (which mainly comprise questionnaires) exclusion criteria: * any suspicion of a medical (orthopaedic, rheumatic or neurological) disease, that can explain the current pain complaints * any suspicion of an (underlying) psychiatric disease, for which psychiatric treatment is better suited, according to the expert opinion of the consultant in rehabilitation medicine. * pregnancy

Keywords: chronic pain adolescent graded exposure
non-invasive evaluation of myocardial stiffness by elastography in pediatric cardiology (elasto-pédiatrie)

Conditions: Dilated Cardiomyopathy; Hypertrophic Cardiomyopathy

Summary: first, investigators must determine the physiological standards across age classes of myocardial stiffness estimated by elastography in ultrafast (estimated right ventricular stiffness \[vd\] and left ventricular \[lv\]). this will be done in groups of children without heart condition, age group (10 children per group, four age groups \[0-1mois, 1 month-1 year 1 year-5 years, 5 years-15years\]). secondly, investigators will evaluate myocardial stiffness elastography (rv and lv) on different groups of children (same age group) with cardiomyopathy and examine correlations with the conventional parameters of systolic and diastolic function of both ventricles and with myocardial strain values. the total population of the study will be 120 children (40 healthy, 80 patients).

monocenter prospective, open-label, non-randomized. all patients included in the study have a specific consultation built around a clinical examination and echocardiography, in two stages, with estimates of the stiffness of the myocardium shearwave elastography (aixplorer®) and measures of all echocardiographic parameters estimated in children with a clinical ultrasound machine (philips and general electric). following this consultation, clinic and electrocardiographic monitoring period will be observed for 30 minutes, to ensure the safety of our procedure. required subjects: 40 healthy volunteers + 80 = 120 persons

Eligibility criteria:
inclusion criteria: group 1. healthy age criteria met by group \[0-1mois, 1 month-1 year 1 year-5 years, 5 years-15years\] * consultation for heart murmur * recipient of a social protection scheme or entitled (excluding ame) * signed informed consent by the holders of parental authority group 2. patients mhc nonobstructive: * age criteria met by group \[1 month-1 year 1 year-5 years\] * diagnostic criteria of non-obstructive hcm validated by the medical team of pediatric cardiology center (necker) * recipient of a social protection scheme or entitled (excluding ame) * signed informed consent by the holders of parental authority group 3. patients primitive cmd: * age criteria met by group \[1 month-1 year 1 year-5 years\] * diagnostic criteria of primary cmd validated by the medical team of pediatric cardiology center (necker) * recipient of a social protection scheme or entitled (excluding ame) * signed informed consent exclusion criteria: group 1. healthy patients: * age\> 15 years * heart and systemic pathology identified * metabolic and tissue pathology. * known genetic pathology may have cardiac involvement. * no echogenicity, * allergy echocardiography gel. group 2. group cmh primitive patients * no echogenicity,, * allergy echocardiography gel. * arrhythmia. * pacemaker or defibrillator group 3. patients primitive cmd: * no echogenicity,, * allergy echocardiography gel. * arrhythmia. * pacemaker or defibrillator

Keywords: child
obstetrical history and anti-hla antibodies level

Conditions: Blood Donors; Anti-HLA Antibody

Summary: chronic histiocytic intervillositis (chi) is associated with severe and recurrent obstetrical complications. a link between anti-hla antibodies (ab) and chi has recently been established. at the etablissement français du sang (efs), donors who have already given birth once and have high levels of anti-hla are excluded from donating apheresis platelets and therapeutic plasma to prevent trali (transfusion related acute lung injury). no studies have examined the obstetrical history of these donors. the question is: is there an association between anti-hla levels and obstetrical complications?

chronic histiocytic intervillositis (chi) is a rare condition with an incidence of around 5 in 10,000 pregnancies. it is defined by major infiltration of the intervillous cavity by cd68+ maternal histiocytes, associated with fibrin deposition on the villous surface. chi is associated with severe obstetrical complications and a very high recurrence rate, estimated at between 70% and 100%. these complications include early and late miscarriage, fetal death, severe growth retardation in surviving fetuses, and premature delivery. the survival rate reported in the literature varies between 30% and 50%. anti-hla antibodies are present in 54% of pregnant women at the end of pregnancy, and their rate increases towards the end of pregnancy. the presence of hla antibodies also increases with the number of pregnancies, and is found in up to 74% of cases after more than 2 deliveries. the research question concerns the existence of a statistically significant association between the presence of high levels of anti-hla antibodies and the occurrence of one or more obstetric complications.

Eligibility criteria:
inclusion criteria: * female blood donors who have been tested for anti-hla antibodies in the context of trali prevention between 2010 and 2020 at efs nouvelle aquitaine \[the donors meet the conditions of the order of december 17, 2019 establishing the selection criteria for blood donors and are over 18 years old, are not protected persons and understand french well\] * women who have already given birth at least once (non-nulliparous women) * women who have not expressed their opposition at the time of donation to participating in a research project and to be contacted exclusion criteria: * none \[donors meet the conditions of the order of december 17, 2019 establishing the selection criteria for blood donors and are over 18 years old, are not protected persons and understand french well\]

Keywords: obstetrical complications levels of anti-hla antibody chronic histiocytic intervillositis
concentrations of voriconazole in blood and bal-fluid after inhalation and oral administration

Conditions: Invasive Aspergillosis

Summary: concentrations of voriconazole in pulmonary epithelial lining fluid and in serum are compared after inhalation of 40 mg voriconazole b.i.d. for two days or oral intake of voriconazole tablets 400 mg bid for 1 day followed by 200 mg b.i.d. for one day, respectively.


Eligibility criteria:
inclusion criteria: * planned bronchoscopy in relation to work-up after hemoptysis or other symptom leading to bronchoscopy * informed written consent * performance status 0-1 * ct scan of thorax without suspicion of malignancy * weight t ≥ 60 og ≤ 130 kg * male gender or female gender in postmenopausal state defined by amenorrhea in more than 12 months. exclusion criteria: * voriconazole treatment up to one week before inclusion * se-creatinin≥ 100 um * alat ≥ 70 u/l * qt-interval \> 480 ms * allergic reaction to voriconazole or constituents in vfend * allergic reaction to other azoles * ischemic heart disease, heart failure or uncontrolled hypertension * treatment with statins or omeprazole, which cannot be paused for three days during voriconazole exposure * treatment with efavirenz, rifabutin, ritonavir, everolimus, methadon, alfentanil, fentanyl, sufentanil, oxycodone, hydrocodone, fluconazole, aztemizol, cisaprid, pimozid, quinidine, terfenadine, carbamazepine, phenobarbital, mephobarbital, ergotamine, dihydroergotamine, rifampicine, st. johns worth, everolimus, phenytoin, warfarin, phenprocoumon, acenocoumarol, benzodiazepines as midazolam, triazolam, alprazolam, sirolimus, cyclosporine, tacrolimus, ibuprofen, diclofenac,tolbutamide, glipizide, vincristine, vinblastine or other vinca alkaloids, hiv-protease inhibitors e.g. saquinavir, amprenavir and nelfinavir, delavirdine, nivrapine and other non-nocleaoside revers transcriptase inhibitors

Keywords: voriconazole inhalation aerosol epithelial lining fluid concentration pharmacokinetic
exercise as an adjunct therapy to reduce blood pressure in chronic kidney disease

Conditions: Focus Chronic Kidney Disease With Hypertension

Summary: the general objective of the study is to investigate the effect of regular aerobic exercise on resting and 24-hr blood pressure levels in men and women with stage 3-4 kidney disease and hypertension.


Eligibility criteria:
inclusion criteria: * • non-diabetic and \>18 years of age * diagnosed kidney disease with associated hypertension: * non-nephrotic range proteinuria at diagnosis * no active glomerular disease or concomitant systemic inflammatory disease (e.g. lupus) * systolic blood pressure \>130 and/or diastolic blood pressure \>80 mm hg (on medication) * an estimated glomerular filtration rate of between 60 ml/min and 15 ml/min. * individuals must be able to provide informed consent * perform walking exercise training on a treadmill * be able to participate in a 12-week supervised exercise program. exclusion criteria: * currently participating in a formal exercise program * diabetes, active glomerular disease, or systemic inflammatory disease * requiring dialysis * have an hematocrit \<27% * uncontrolled hypertension (\>200/110mmhg) * peripheral vascular disease. * an inability to understand english or give consent. other exclusion criteria are: any contraindications to exercise testing or training as indicated by the american college of sports medicine guidelines such as: unstable coronary heart disease and symptomatic heart failure, exercise capacity limited by health problems such as angina, severe arthritis, or extreme dyspnea on exertion, progressive neuromuscular disease, pulmonary disease, or having undergone a coronary revascularization within the past 6 months prior to enrollment.

Keywords: exercise blood pressure chronic kidney disease